Tirzepatide 60mg | GIP/GLP-1

Tirzepatide  GIP/GLP-1 – Bulk Tirzepatide is a dual GIP/GLP-1

Tirzepatide is a dual GIP/GLP-1 receptor agonist approved for type 2 diabetes and weight management, working by increasing insulin sensitivity, reducing appetite, and slowing gastric emptying. While standard FDA-approved pens (Zepbound/Mounjaro) peak at 15mg weekly, a 60mg total vial amount refers to compounded, multi-dose formulations.

Key Details on Tirzepatide (GIP/GLP-1):

• Mechanism: Acts as both a Glucose-dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) receptor agonist.
• Effectiveness: Clinical trials (SURPASS/SURMOUNT) showed superior weight loss (up to 21%) and glycemic control (A1C reduction) compared to selective GLP-1 agonists.
• Dosage & Administration: Weekly subcutaneous injections. Standard doses are 5 mg, 10 mg, or 15 mg.
• Compounded 60mg Formulation: Often sold in compounding pharmacy vials (e.g., 60mg total volume) rather than commercial pens. It is crucial to determine the concentration (mg/mL) from a pharmacist to calculate the correct dosage, as 60mg is not a single dose.
• Side Effects: Primarily gastrointestinal, including nausea, vomiting, diarrhea, and constipation, especially when increasing

#PeptideBlend #ResearchPeptides #InjectableBlend #PeptideResearch #LabResearch #RetaPharmaLab #ResearchUseOnly #GHKCuBlend #TB500Research #BPC157Research #PeptideFormula #AdvancedResearch #WellnessResearch #PeptideScience #BiotechResearch #ResearchLab #PeptideInjection #LabGradePeptides #ResearchChemical #ScientificResearch #PremiumBlend